Earlier this month, Novavax completed submission of the final data package for FDA approval of its vaccine, the last prerequisite in the emergency use authorization application process. It must wait one month after that submission to formally apply for EUA, in accordance with submission guidance. The FDA application will come about six months after Novavax had originally intended to file. In December, Novavax received authorization for its vaccine in India, as well as the European Union. Its two-dose vaccine is already being distributed in Indonesia and the Philippines. Authorization is pending in other countries, including Japan. Novavax received $1.6 billion for the federal government in 2020 to develop and manufacture a COVID vaccine, part of Operation Warp Speed. More Coronavirus News Looking for more information? D.C., Maryland and Virginia are each releasing more data every day. Visit their official sites here: Virginia | Maryland | D.C.